499139-27-4

Basic information

• Product Name: 2-BOC-6-METHOXY-3,4-DIHYDRO-1H-ISOQUINOLINE-1-CARBOXYLIC ACID
• Synonyms: 2-BOC-6-METHOXY-3,4-DIHYDRO-1H-ISOQUINOLINE-1-CARBOXYLIC ACID;1,2(1H)-Isoquinolinedicarboxylic acid, 3,4-dihydro-6-methoxy-, 2-(1,1-dimethylethyl) ester;2-(tert-butoxycarbonyl)-6-Methoxy-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid;3,4-dihydro-6-methoxy-1,2(1H)-Isoquinolinedicarboxylic acid 2-(1,1-dimethylethyl) ester
• CAS NO: 499139-27-4
• Molecular Formula: C₁₆H₂₁NO₅
• Molecular Weight: 307.34
• Mol File: 499139-27-4.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 475.4°C at 760 mmHg
• Flash Point: 241.3°C
• Appearance: /
• Density: 1.225g/cm³
• Vapor Pressure: 7.59E-10mmHg at 25°C
• Refractive Index: 1.547
• PKA: 3.65±0.20(Predicted)
• CAS DataBase Reference: 2-BOC-6-METHOXY-3,4-DIHYDRO-1H-ISOQUINOLINE-1-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BOC-6-METHOXY-3,4-DIHYDRO-1H-ISOQUINOLINE-1-CARBOXYLIC ACID(499139-27-4)
• EPA Substance Registry System: 2-BOC-6-METHOXY-3,4-DIHYDRO-1H-ISOQUINOLINE-1-CARBOXYLIC ACID(499139-27-4)

Safety Data

• Hazardous Substances Data: 499139-27-4(Hazardous Substances Data)

Usage

General Description

2-BOC-6-METHOXY-3,4-DIHYDRO-1H-ISOQUINOLINE-1-CARBOXYLIC ACID is a chemical compound typically used in research and development, often in labs to aid in life sciences research. As a derivative of isoquinoline, which is a heterocyclic compound, it shares characteristics with other organic compounds, such as benzene and pyridine, and contains both carbon and nitrogen atoms. Its physical and chemical properties, such as molecular weight and the nature of its bonds, can influence its behavior in various contexts and applications. Due to its highly specific nature and properties, potential uses of 2-BOC-6-METHOXY-3,4-DIHYDRO-1H-ISOQUINOLINE-1-CARBOXYLIC ACID are focused mainly within scientific research and development scopes, but the full extent of its uses and potential in broader pharmaceutical or chemical manufacturing contexts may not yet be fully explored.

InChI:InChI=1/C16H21NO5/c1-16(2,3)22-15(20)17-8-7-10-9-11(21-4)5-6-12(10)13(17)14(18)19/h5-6,9,13H,7-8H2,1-4H3,(H,18,19)

Upstream product

• 2039-67-0 2-(3-methoxyphenyl)-1-ethanamine 
• 362492-00-0 2-(tert-butoxycarbonyl)-6-hydroxy-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid 
• 350014-18-5 1,2,3,4-Tetrahydro-6-hydroxy-1-isoquinolinecarboxylic acid methyl ester 
• 38449-59-1 2-(3-hydroxyphenyl)ethylamine hydrobromide 
• 91523-50-1 rac-6-hydroxy-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid 
• 588-05-6 m-tyramine 
• 1068562-72-0 C₂₁H₂₉NO₇ 
• 3458-98-8 3-hydroxyphenylethylamine hydrochloride 
• 128073-49-4 ethyl (1SR)-6-hydroxy-2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 350014-19-6 methyl N-(tert-butyloxycarbonyl)-6-hydroxy-3,4-dihydro-1H-isoquinoline-1-carboxylate 
• 531556-16-8 C₁₇H₂₃NO₅ 
• 128073-50-7 ethyl (1SR)-6-hydroxy-1,2,3,4-tetrahydroisoquinoline-1-carboxylate hydrochloride 

Downstream Products

• 1430216-08-2 (E)-4-(2-(3-(5-chloro-2-(1H-tetrazol-1-yl)phenyl)acryloyl)-6-methoxy-1,2,3,4-tetrahydroisoquinoline-1-carboxamido)benzoic acid 
• 1447733-07-4 4-(6-methoxy-1,2,3,4-tetrahydroisoquinoline-1-carboxamido)benzoic acid trifluoracetate 

Relevant articles and documents

Discovery of orally efficacious RORγt inverse agonists. Part 2: Design, synthesis, and biological evaluation of novel tetrahydroisoquinoline derivatives

A series of tetrahydroisoquinoline derivatives were designed, synthesized, and evaluated for their potential as novel orally efficacious retinoic acid receptor-related orphan receptor-gamma t (RORγt) inverse agonists for the treatment of Th17-driven autoimmune diseases. We carried out cyclization of the phenylglycinamide core by structure-based drug design and successfully identified a tetrahydroisoquinoline carboxylic acid derivative 14 with good biochemical binding and cellular reporter activity. Interestingly, the combination of a carboxylic acid tether and a central fused bicyclic ring was crucial for optimizing PK properties, and the compound 14 showed significantly improved PK profile. Successive optimization of the carboxylate tether led to the discovery of compound 15 with increased inverse agonistic activity and an excellent PK profile. Oral treatment of mice with compound 15 robustly and dose-dependently inhibited IL-17A production in an IL23-induced gene expression assay.

Heterocyclic compound

The present invention relates to compound (I) or a salt thereof which has a ROR γ t inhibitory action. wherein each symbol is as defined in the specification.

SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS

The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.